13 Aug 2026quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.4 million and a net loss of $6.3 million for the period ended 2026-06-30.
Announcements, explained
Each one in plain English, with the numbers worked through for a shareholder.
13 Aug 2026quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.4 million and a net loss of $6.3 million for the period ended 2026-06-30.
10 Aug 2026listing compliance notice▼ BadMajor
Arcadia fell below Nasdaq's $1.00 minimum bid price requirement for a third time (after 2017 and 2022) -- the clearest sign yet of the company's prolonged distress following the Roosevelt merger's collapse.
9 July 2026securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
26 June 2026securities registration● Neutral
Arcadia Biosciences, Inc. filed notice of an exempt private placement.
26 June 2026securities registration● Neutral
Arcadia Biosciences, Inc. registered a securities offering with the SEC using its shelf eligibility.
15 June 2026capital raising announcement▼ BadMajor
Arcadia raised about $4 million in another pre-funded-warrant-and-options private placement, priced at $1.0299 per unit -- continued reliance on dilutive, option-heavy financing to stay funded after the failed Roosevelt merger.
15 May 2026substantial holder notice● Neutral
Armistice Capital, LLC disclosed a new substantial Arcadia Biosciences, Inc. shareholding (7.75% of votes).
14 May 2026quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.1 million and a net loss of $4.4 million for the period ended 2026-03-31.
14 May 2026quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.1 million and a net loss of $4.4 million for the period ended 2026-03-31.
3 Apr 2026auditor change▼ BadMajor
Arcadia dismissed Deloitte as its independent auditor. Deloitte's own audit reports had carried a going-concern qualification over Arcadia's accumulated deficit and insufficient cash resources, and the company's 10-K disclosed material weaknesses in internal controls -- serious financial-health warning signs, even though there was no disagreement with Deloitte over accounting matters.
11 Feb 2026securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
28 Jan 2026securities registration● Neutral
Arcadia Biosciences, Inc. registered a securities offering with the SEC using its shelf eligibility.
27 Jan 2026securities registration● Neutral
Arcadia Biosciences, Inc. filed notice of an exempt private placement.
20 Jan 2026listing compliance notice▼ Bad
Arcadia Biosciences, Inc. withdrew a registration statement, abandoning the offering it covered.
14 Jan 2026capital raising announcement▼ BadMajor
Weeks after the Roosevelt deal collapsed, Arcadia induced holders of older investment options (originally priced at $9.00, issued across four financings from Dec 2020 through Mar 2023) to exercise at a steeply reduced $2.575, raising about $2.1 million -- in exchange, holders got new options at an even lower $2.325 strike -- another round of option-recycling to raise emergency cash.
29 Dec 2025material agreement termination▼ BadMajor
Roosevelt terminated the Exchange Agreement -- the deal never closed by its extended deadline -- ending Arcadia's year-long attempt to reverse-merge in an oil-and-gas business. Neither side owes a break-up fee, but Arcadia remains a standalone shell facing the same cash constraints the S-4 had warned about.
7 Nov 2025quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and net income of $856 thousand for the period ended 2025-09-30.
7 Nov 2025quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and net income of $856 thousand for the period ended 2025-09-30.
19 Aug 2025substantial holder notice● Neutral
Arcadia Biosciences, Inc. disclosed a new substantial Arcadia Biosciences, Inc. shareholding (5.08% of votes).
14 Aug 2025quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.5 million and a net loss of $4.5 million for the period ended 2025-06-30.
14 Aug 2025quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.5 million and a net loss of $4.5 million for the period ended 2025-06-30.
31 July 2025business combination▼ BadMajor
Amendment No. 1 to the registration statement for Arcadia's reverse takeover by Roosevelt Resources LP, now written around the April 25, 2025 first amendment to the exchange agreement. Arcadia would issue 12,303,360 shares to Roosevelt's limited partners, leaving them with 90% of the company and existing Arcadia shareholders with 10% - plus a reverse-split proposal on the same ballot - against a Northland fairness opinion that put an implied enterprise value of about $47 million on the Texas oil and gas business coming in.
12 May 2025director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Mark Kawakami received a stock option grant for 12,500 shares.
12 May 2025director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Executive Officer Thomas J. Schaefer received a stock option grant for 12,500 shares.
8 May 2025quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $1.2 million and net income of $2.6 million for the period ended 2025-03-31.
8 May 2025quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $1.2 million and net income of $2.6 million for the period ended 2025-03-31.
2 May 2025material agreement● NeutralMajor
The Roosevelt Exchange Agreement's termination deadline was pushed back three months, from May 15 to August 15, 2025 -- signaling the deal was taking longer to close than originally planned.
3 Apr 2025material agreement● Neutral
Arcadia settled with an unnamed licensing counterparty: the counterparty returned certain previously-licensed IP rights and paid Arcadia $750,000, while Arcadia transferred its reduced-gluten and oxidative-stability wheat patent portfolios to the counterparty and gave up any future royalty rights under the older agreement -- a modest legacy-IP cleanup running alongside the pending Roosevelt transaction.
14 Feb 2025business combination● NeutralMajor
This is the document in which Arcadia Biosciences stops being an agricultural company: it would issue 12,284,475 shares -- about $34.5 million at $2.77 -- to the partners of Roosevelt Resources LP, a Texas oil and gas partnership, in exchange for all of Roosevelt's equity, leaving Roosevelt's limited partners with roughly 90% of Arcadia and existing Arcadia shareholders with about 10% (contractually never less than 80/20). Shareholders were asked to approve a 1-for-2 to 1-for-5 reverse split alongside it, and Arcadia warned that without the deal or another funding source it could have to cut back, seek bankruptcy protection or dissolve.